Log in
Enquire now
‌

US Patent 8252905 Anti-CD14 antibody fusion protein

Patent 8252905 was granted and assigned to Mochida Pharmaceutical on August, 2012 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
‌
Mochida Pharmaceutical
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
82529050
Patent Inventor Names
Yoshitaka Hosaka0
Shoji Furusako0
Takashi Takeuchi0
Tetsushi Kawahara0
Kazuyuki Nakayama0
Masaki Nakamura0
Date of Patent
August 28, 2012
0
Patent Application Number
117918880
Date Filed
June 5, 2006
0
Patent Citations Received
‌
US Patent 11965017 Serpin fusion polypeptides and methods of use thereof
0
‌
US Patent 11754566 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
‌
US Patent 11761967 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Patent Primary Examiner
‌
Sharon Wen
0
Patent abstract

A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8252905 Anti-CD14 antibody fusion protein

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.